A PHP Error was encountered

Severity: Warning

Message: fopen(/var/lib/php/sessions/ci_session8sn5lqsldr241dmb86g0csvvu7mo18sd): Failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 177

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)

Filename: Session/Session.php

Line Number: 137

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

The Mitris RESILIA Valve: New Skin for a Proven Design. | LitMetric

AI Article Synopsis

  • The mitris valve combines features of two existing valves—the Carpentier-Edwards PERIMOUNT Magna Mitral Ease valve and INSPIRIS RESILIA tissue—for enhanced hemodynamic performance and durability.
  • Its design includes a more flexible, saddle-shaped sewing cuff that fits the mitral valve better, reducing risks of complications during double-valve replacements.
  • The valve also benefits from advanced technology that minimizes free aldehyde levels, suggesting improved long-term durability and reliability compared to earlier models.

Article Abstract

By incorporating the best features of the Carpentier-Edwards PERIMOUNT Magna Mitral Ease valve (Edwards Lifesciences Corporation, Irvine, California) and INSPIRIS RESILIA tissue (Edwards Lifesciences Corporation, Irvine, California), the mitris valve inherits the advantages of the remarkable hemodynamic performance of the former and the durability of the latter. In this paper, we will summarize the process that led to the creation of this new valve and report on the first implant's feasibility and first impression. The mitris valve has an overall implantability profile, overlapping the previous generation with no added challenges, but compared to the PERIMOUNT Magna Mitral Ease valve, the mitris valve boasts a more pliable saddle-shaped sewing cuff that is specifically tailored to fit the complex structure of the mitral valve with a lower stent height. This could be particularly beneficial in the context of double-valve replacement, as it may prevent any disturbance to the bioprosthesis located in the aortic position in small annulus. This could also prevent some rare but unpleasant complications such as left ventricle outflow obstruction or rupture of the atrioventricular sulcus. In addition, it could allow for better adherence to the saddle-shaped annulus of the mitral valve with the possibility of less stress (and therefore fibrosis) on the valve tissue, while further reducing the degeneration time. Furthermore, thanks to the possibility of being temporarily adjusted inwards, it is possible to ensure greater implantability compared to the previous generation of Magna Edwards mitral valves. Thanks to INSPIRIS technology, which prevents the generation of free aldehydes that promote oxidation and calcification of pericardial tissue, it is possible to assume that the durability will probably also improve. This reinforces the trustworthiness of the mitris valve.

Download full-text PDF

Source
http://dx.doi.org/10.52198/24.STI.44.CV1792DOI Listing

Publication Analysis

Top Keywords

mitris valve
16
valve
11
perimount magna
8
magna mitral
8
mitral ease
8
ease valve
8
edwards lifesciences
8
lifesciences corporation
8
corporation irvine
8
irvine california
8

Similar Publications

Article Synopsis
  • The mitris valve combines features of two existing valves—the Carpentier-Edwards PERIMOUNT Magna Mitral Ease valve and INSPIRIS RESILIA tissue—for enhanced hemodynamic performance and durability.
  • Its design includes a more flexible, saddle-shaped sewing cuff that fits the mitral valve better, reducing risks of complications during double-valve replacements.
  • The valve also benefits from advanced technology that minimizes free aldehyde levels, suggesting improved long-term durability and reliability compared to earlier models.
View Article and Find Full Text PDF

The use of bioprostheses is increasing in younger patients, but it is associated with the risk of later valve deterioration, especially in the mitral position. A new bioprosthesis for mitral valve replacement offers possible longer-term durability and improved hemodynamics. : Here, we report the implantation of the novel Edwards MITRIS RESILIA mitral valve (Edwards Lifesciences Inc.

View Article and Find Full Text PDF

An 82-year-old woman was referred to our hospital because of severe mitral valve regurgitation( MR)with symptoms of heart failure. Preoperative transesophageal echocardiography( TEE) showed P2 prolapse due to chordal rupture, severe calcification of P2, and mild tricuspid valve regurgitation. The patient underwent mitral valve replacement using the MITRIS RESILIA mitral valve and tricuspid annuloplasty.

View Article and Find Full Text PDF

We report the first successful implantation in the United States of a novel mitral valve (MITRIS RESILIA by Edwards Lifesciences) in a patient with history of mitral valve replacement at a young age. This new bioprosthetic valve offers a unique profile and innovative option for mitral valve replacement in patients who are at risk of left ventricular outflow tract obstruction.

View Article and Find Full Text PDF

Objective: Evaluate transcatheter mitral valve replacement (TMVR) valve-in-valve (VIV) outcomes in three different mitral bioprostheses (of comparable measured internal diameters) under stable hemodynamic and surgical conditions by bench, echocardiographic, computerized tomography (CT), and autopsy comparisons pre- and post-valve implantation in a porcine model under matched controlled conditions.

Background: Impact of surgical bioprosthesis design on TMVR VIV procedures is unknown.

Methods: Fifteen similar-sized Yorkshire pigs underwent pre-procedural CT screening.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!